• Atossa Therapeutics posted a net loss of USD 9.6 million for the quarter ended March 31, 2026, while reporting no revenue.
• Operating expenses climbed 33.78% to USD 9.9 million, led by a 15% rise in R&D spending to USD 4.78 million.
• G&A costs rose 56% to USD 5.09 million, driven by higher legal fees tied to patent litigation and intellectual property matters.
• Cash and cash equivalents totaled USD 31.7 million at quarter-end as net cash used in operating activities widened to USD 9.58 million; management said existing resources likely will be insufficient to fund planned operations for the next 12 months.
• Company entered a new at-the-market facility for up to USD 50 million, made no sales under the program through the filing date, and said top-line durability data from Karisma-(Z)-endoxifen is expected before end of Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atossa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-213423), on May 08, 2026, and is solely responsible for the information contained therein.